Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tularemia


Facebook
        Twitter
        LinkedIn
        Syndicate





Managing potential laboratory exposures to *Francisella tularensis*								Related Pages
										lab image showing glass vialsManaging potential laboratory exposures to Francisella tularensis pdf icon[PDF – 1 page]
*Francisella tularensis*is highly infectious when grown in culture, and laboratory-acquired infections have been documented. The isolation of *F. tularensis* from clinical specimens, especially if unanticipated, can generate concern among laboratory workers about possible exposure.
Management options for potentially exposed workers include a “fever watch” or antimicrobial prophylaxis. During a fever watch, workers monitor their temperature with instructions to seek immediate treatment for tularemia if they develop a fever (usually defined as a single oral temperature above 101 °F or 38.5 °C).
There are no set criteria for determining who should be managed by fever watch and who would benefit from immediate prophylaxis. Factors to consider when making this decision include:
Nature of the exposure — Workers who report sniffing a culture plate or conducting procedures that generate aerosols are probably at greater risk than those who simply worked with the organism on the bench.
Incubation period — The typical incubation period for tularemia is 3–7 days (range 1–14 days). Much of this period may have passed by the time the organism is positively identified, in which case, the remaining risk of infection is low.
Level of concern — Some laboratory workers may be very anxious regarding their risk of infection, while others may be more concerned about taking medications unnecessarily.Doxycycline (100 mg orally BID X 14 days) is generally recommended for prophylaxis in adults. Ciprofloxacin (500 mg orally BID) is not FDA-approved for prophylaxis of tularemia but has demonstrated efficacy in various studies, and may be an alternative for patients unable to take doxycycline.
										
							
								Page last reviewed:  December 13, 2018						Content source:  	Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD) Tularemia Home
Transmission
Signs & Symptoms
Diagnosis & Treatment
Prevention
Statistics
For Clinicians
For Public Health Officials
Frequently Asked Questions
Publications
Managing Laboratory Exposures


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue